Detalles de la búsqueda
1.
Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis.
Mycoses;
63(9): 900-910, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32531854
2.
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax.
Am J Hematol;
98(4): E80-E83, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36651870
3.
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.
Am J Hematol;
92(10): 1037-1046, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28675513
4.
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.
Ann Hematol;
95(7): 1059-65, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27091349
5.
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.
Eur J Haematol;
96(4): 344-51, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26018238
6.
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Eur J Haematol;
95(1): 52-6, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25764148
7.
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study.
Ann Hematol;
93(8): 1413-20, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24647684
8.
Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.
Cancer;
118(22): 5544-9, 2012 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22786730
9.
Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience.
Cancers (Basel);
14(19)2022 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36230820
10.
Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?
J Clin Med;
11(9)2022 May 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35566719
11.
[Out-patient management of nausea and vomiting in multiday therapy of acute myeloid leukemia in the elderly. Use of granisetron in slow-release transdermal formulation. Clinical case]. / Gestione out-patient di nausea e vomito nella terapia multi-day della leucemia acuta mieloide dell'anziano. Utilizzo di granisetron nella formulazione transdermica a lento rilascio in un caso clinico.
Recenti Prog Med;
110(3): 10e-13e, 2019 Mar.
Artículo
en Italiano
| MEDLINE | ID: mdl-30968859
12.
A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.
Mediterr J Hematol Infect Dis;
9(1): e2017046, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28698789
13.
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.
Blood Cancer J;
12(9): 132, 2022 09 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36071048
14.
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
J Clin Oncol;
31(21): 2671-7, 2013 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-23796988
Resultados
1 -
14
de 14
1
Próxima >
>>